Benefits of the maintenance approach include sustained appetite regulation, continued metabolic support, fewer side effects at lower doses, and easier dose escalation if weight begins to creep
Has your weight changed before, but not now
HF: HR = 1.00, 95% CI 0.821.24, p interaction = 0.12), CV death (no HF: HR = 0.81, 95% CI 0.710.92
Wegovy (semaglutide) is a GLP-1 receptor agonist licensed for chronic weight management in adults and adolescents with obesity
Prevalence of eating disorder The systematic analysis of the selected studies indicates that about 8% of respondents have eating disorders and 3% experience recurrent episodes
Wegovy Tablets Wegovy Tablets Wegovy Tablets Can affect appetite and food cravings Patients lost 16.6% of body weight on average with lifestyle changes* Available from 19.99 a week *OASIS 4 trial, oral semaglutide 25mg, 16.6% mean weight loss at Week 64 amongst adherent participants